CT
CORT icon

Clearstead Trust’s Corcept Therapeutics CORT Stock Holding History

Clearstead Trust’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91K Buy
22
+14
+175% +$845 ﹤0.01% 888
2026
Q1 		$323 Sell
8
-9
-53% -$337 ﹤0.01% 978
2025
Q4 		$592 Sell
17
-51
-75% -$4.01K ﹤0.01% 975
2025
Q3 		$5.65K Buy
68
+17
+33% +$1.23K ﹤0.01% 739
2025
Q2 		$3.74K Buy
+51
New +$3.7K ﹤0.01% 811

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Trust's CORT Position: Q2 2026 in Review

Clearstead Trust increased its Corcept Therapeutics (CORT) stake by 175% in Q2 2026, buying an estimated $845 and bringing the position to 22 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #888.

Clearstead Trust first reported a position in CORT in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.65K in Q3 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Clearstead Trust held 22 shares of Corcept Therapeutics worth $1.91K as of Q2 2026.
  • Clearstead Trust bought 14 Corcept Therapeutics shares in Q2 2026, an estimated $845.
  • Corcept Therapeutics made up ﹤0.01% of Clearstead Trust's portfolio in Q2 2026, its #888 holding.
  • Clearstead Trust first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Clearstead Trust's Corcept Therapeutics position peaked at $5.65K in Q3 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Clearstead Trust's 13F filing for Q2 2026, filed 6 Aug 2026.